These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1382234)

  • 1. Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.
    Koza I; Mardiak J; Bohunický L; Svancárová L; Fuchsberger P; Gyárfás J; Horák I; Spánik S; Sufliarsky J; Thalmeinerová Z
    Neoplasma; 1992; 39(1):43-7. PubMed ID: 1382234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
    Connors JM; Klimo P
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):41-6. PubMed ID: 2456622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol].
    Montalbán C; Rodríguez García JL; Marcos Robles J; Serrano M; Arechaga S; Perales J; Bellas C
    Med Clin (Barc); 1991 Oct; 97(14):521-5. PubMed ID: 1721672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
    Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
    Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
    Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):67-73. PubMed ID: 7507314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avascular necrosis of bone mimicking symmetric polyarthritis in a patient with malignant lymphoma treated with high-dose steroids.
    Buskila D; Thomson GT; Klein M; Keystone EC
    Isr J Med Sci; 1992 Nov; 28(11):804-5. PubMed ID: 1281809
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
    Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
    Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
    Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
    Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
    Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.